ClinicalTrials.gg
RecruitingNCT05377307Updated Oct 9, 2026

Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy

An observational study in Diffuse Large B Cell Lymphoma, Large B-cell Lymphoma and Primary Mediastinal Large B Cell Lymphoma, sponsored by Pell Bio-Med Technology Co., Ltd.. Recruiting at 5 sites in Taiwan. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Pell Bio-Med Technology Co., Ltd. · Observational

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 7 months later.
Updated Oct 9, 2026Start date movedStudy contact changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
49
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 37 studies in Lymphoma, Large B-Cell, Diffuse with a site in Taiwan — 5 open to participants now, 19 under way, 10 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Taiwan.

Started
2023
with 4 others
Observational
3 of 37
1 open now
Primary completion
2036-12
later than 18 of 18 live
Registered
29th of 37
by date
Lead sponsor
2 of 37
Pell Bio-Med Technology Co., Ltd.

Among the 37 studies in Lymphoma, Large B-Cell, Diffuse with a site in Taiwan, this one is one of 5 that started in 2023, is one of 3 observational ones, reaches primary completion later than 18 of the 18 other live ones, and was the 29th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

5 of the 37 studies in Lymphoma, Large B-Cell, Diffuse with a site in Taiwan are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Lymphoma, Large B-Cell, Diffuse with a site in Taiwan, or all of them as a file.
02

Study summary

According to health authorities guidances (FDA 2006, EMA(European Medicines Agency) 2009) for gene therapy clinical trials, observing subjects for delayed adverse events for 15 years is recommended. This purpose of this long-term follow-up study is to evaluate the safety and efficacy in patients who have ever received lentiviral-based gene-edited immune cells which are manufactured by Pell Bio-Med Technology Co. Ltd.

Read the detailed description

After completion or early withdraw from the other treatment protocol, patients should be enrolled into this long-term follow-up study. If patients do not enter this study right after leaving the treatment protocol, they may have the option to enter this long-term follow-up study at any time within 15 years after the last lentiviral-based gene-edited immune cell infusion.

03

Conditions studied

  • Diffuse Large B Cell Lymphoma
  • Large B-cell Lymphoma
  • Primary Mediastinal Large B Cell Lymphoma
  • Follicular Lymphoma Grade 3A
  • Follicular Lymphoma Grade 3B

Keywords

  • DLBCL(Diffuse Large B Cell Lymphoma)
  • PMLBCL(Primary Mediastinal Large B Cell Lymphoma)
  • FL(Follicular Lymphoma)
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes all patients who have ever received Pell's lentiviral-based gene-edited immune cell therapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must have ever received Pell's lentiviral-based gene-edited immune cell as monotherapy or as combination therapy in clinical trials.
  2. The last lentiviral-based gene-edited immune cell infusion within 15 years.
  3. Patient/patient's parent/legal guardian is capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

Exclusion Criteria:

There are no specific exclusion criteria for this study.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
49 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Group A

    After completion or early withdraw from the treatment protocol, patients will be enrolled into this long-term follow-up study. If patients do not enter this study right after leaving the treatment protocol, they may have the option to enter this study at any time within 15 years after the last lentiviral-based gene-edited immune cell infusion.

    Genetic: Pell's lentiviral-based gene-edited immune cell therapy

  • Group B

    Some patients may require joining other Pell's gene-edited immune cell therapy study during participating in this long-term follow-up study. For such case, the patient could be enrolled into the new treatment protocol. Meanwhile, the patient can be remaining in this long-term follow-up protocol as an inactive participant.

    Genetic: Pell's lentiviral-based gene-edited immune cell therapy

Interventions

  • GeneticPell's lentiviral-based gene-edited immune cell therapy

    No study drug or other planned treatment will be administered. Subjects who previously received Pell's lentiviral-based gene-edited immune cell therapy will be evaluated the safety and efficacy.

06

What researchers measure

Primary outcomes

  1. To assess delayed adverse events which are suspected related to previous gene-edited immune cell therapy

    • Proportion of patients with any events of the following items which are suspected related to previous gene-edited immune cell therapy. 1. New malignancies 2. New incidence or exacerbation of a pre-existing neurologic disorder 3. New incidence or exacerbation of a prior rheumatologic or other autoimmune disorder 4. New incidence of a hematologic disorder, including hypogammaglobulinemia 5. New incidence of infection (potentially product-related) 6. Other than the above adverse events, which are suspected related to gene-edited immune cell therapy judged by the investigator

    Time frame: 15 years

Secondary outcomes

  1. Monitor for Replication Competent of Lentivirus (RCL)

    Proportion of patients with detectable RCL in peripheral blood by VSV-G(Vesicular stomatitis virus G) qPCR

    Time frame: 15 years

  2. Monitor the persistence of gene-edited immune cells in peripheral blood(By qPCR)

    Proportion of patients with detectable transgene level in peripheral blood by qPCR

    Time frame: 15 years

  3. Monitor the persistence of gene-edited immune cells in peripheral blood(By Flowcytometry)

    Persistence of gene-edited immune cells in peripheral blood using flow cytometry

    Time frame: 5 years

  4. To assess the long-term efficacy of gene-edited immune cells

    1. Proportion of patients with relapse or progress among patients who didn't progress or relapse at study entry/reentry 2. Incidence of death

    Time frame: 15 years

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2036, 165 months after the start.

Of 66 observational studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 114. This study's planned 165 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Dec 2022 → Mar 2023, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2022
First posted
May 17, 2022
StartActual
Mar 31, 2023was Dec 2022
Primary completionEst.
Dec 2036
CompletionEst.
Dec 2037
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 5 sites removed
Show 5 added (5 Taiwan)
  • Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung, Taiwan
  • National Taiwan University Hospital · Taipei, Taiwan
  • Taipei Veterans General Hospital · Taipei, Taiwan
  • Chi Mei Medical Center · Tainan, Taiwan
  • Taipei Medical University - Taipei Medical University Hospital · Taipei, Taiwan
Show 5 removed
  • Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung, Taiwan
  • Chi Mei Medical Center · Tainan City, Taiwan
  • Taipei Medical University - Taipei Medical University Hospital · Taipei city, Taiwan
  • National Taiwan University Hospital · Taipei, Taiwan
  • Taipei Veterans General Hospital · Taipei, Taiwan
Oct 9, 2026
Start date
Dec 29, 2022→Mar 31, 2023
Oct 9, 2026
Contact
Study contact changed: c•••@pellbmt.com · •••1789→h•••@pellbmt.com · •••1789. See the current contact
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    5 sites added, 5 sites removed
    Show 5 added (5 Taiwan)
    • Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung, Taiwan
    • National Taiwan University Hospital · Taipei, Taiwan
    • Taipei Veterans General Hospital · Taipei, Taiwan
    • Chi Mei Medical Center · Tainan, Taiwan
    • Taipei Medical University - Taipei Medical University Hospital · Taipei, Taiwan
    Show 5 removed
    • Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung, Taiwan
    • Chi Mei Medical Center · Tainan City, Taiwan
    • Taipei Medical University - Taipei Medical University Hospital · Taipei city, Taiwan
    • National Taiwan University Hospital · Taipei, Taiwan
    • Taipei Veterans General Hospital · Taipei, Taiwan
    Start date Dec 29, 2022→Mar 31, 2023
    Contact Study contact changed: c•••@pellbmt.com · •••1789→h•••@pellbmt.com · •••1789. See the current contact
    + 3 other changes: index terms, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05377307
Lead sponsor
Pell Bio-Med Technology Co., Ltd.
Responsible party
Sponsor
First posted
May 17, 2022
Start date
Mar 31, 2023
Primary completion
Dec 2036 (estimated)
Completion
Dec 2037 (estimated)
Last update
Oct 9, 2026

Study contacts

T. Hsun Lin, MSc
Contact
hsun.lin@pellbmt.com
886-2-8791-1789 ext. 3111
Chen-Lung Lin, MD
study chair · Pell Bio-Med Technology Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion